Shenzhen Exeplastic Technology Co., Ltd – Trademark Portfolio

Entity Type: 99

Shenzhen Exeplastic Technology Co., Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ANPVAPE. The owner is based in Shenzhen, Guangdong.

3-29C,Unit 3,Bldg.1,Meiguijun,Longping

West Rd,Longcheng St,Longgang Dist

Shenzhen, Guangdong 518100 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ANPVAPE
ANPVAPE
Registered 2024

Trademark Classifications

Shenzhen Exeplastic Technology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhen Exeplastic Technology Co., Ltd have?

Shenzhen Exeplastic Technology Co., Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Exeplastic Technology Co., Ltd file in?

Shenzhen Exeplastic Technology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhen Exeplastic Technology Co., Ltd's most well-known trademarks?

Shenzhen Exeplastic Technology Co., Ltd's registered trademark portfolio includes well-known marks such as ANPVAPE. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Exeplastic Technology Co., Ltd's trademark registration success rate?

Shenzhen Exeplastic Technology Co., Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.